Cargando…

The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer

BACKGROUND: Fluoroquinolones are used for infection prevention in high-risk patients with haematological malignancies. Fluoroquinolones are active against many Gram-negative bacilli (GNB) but are less active against Gram-positive organisms. We evaluated the in vitro activity of delafloxacin and sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerges, Bahgat, Rolston, Kenneth, Shelburne, Samuel A, Rosenblatt, Joel, Prince, Randall, Raad, Issam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041357/ https://www.ncbi.nlm.nih.gov/pubmed/36994231 http://dx.doi.org/10.1093/jacamr/dlad034

Ejemplares similares

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer
por: Rolston, Kenneth, et al.
Publicado: (2023)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
por: Rolston, Kenneth V. I., et al.
Publicado: (2020)

2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
por: Gerges, Bahgat Z, et al.
Publicado: (2023)

2124. Novel Polygalacturonic and Caprylic Acid (PG+CAP) Antimicrobial Wound Ointment Effectiveness in Eradicating C. auris Biofilms In Vitro
por: Truong, Y Lan, et al.
Publicado: (2023)

2123. Novel Antimicrobial Polycarbonate Coating for Intravenous Connectors
por: Truong, Y Lan, et al.
Publicado: (2023)

683. Assessment of Biofilm Eradication and Cytotoxicity of a Novel Polygalacturonic Acid + Caprylic Acid Wound Ointment Compared with Antiseptic Wound Ointments
por: Gerges, Bahgat, et al.
Publicado: (2019)

810. Resistance to the Minocycline-Rifampin-Chlorhexidine (MRCH) combination does not emerge in biofilms of Tetracycline and Rifampin resistant bacteria grown on MRCH catheters depleted below antimicrobially effective concentrations
por: Gerges, Bahgat, et al.
Publicado: (2020)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

Enhanced Biofilm Eradication and Reduced Cytotoxicity of a Novel Polygalacturonic and Caprylic Acid Wound Ointment Compared with Common Antiseptic Ointments
por: Gerges, Bahgat Z., et al.
Publicado: (2021)

The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review
por: Reitzel, Ruth A, et al.
Publicado: (2020)

1163. Minocycline EDTA Ethanol (MEDTA+EtOH) Lock Is Highly Efficacious in Rapidly Eradicating Candida auris Biofilm
por: Reitzel, Ruth A, et al.
Publicado: (2019)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Insights on the Role of Antimicrobial Cuffed Endotracheal Tubes in Preventing Transtracheal Transmission of VAP Pathogens from an In Vitro Model of Microaspiration and Microbial Proliferation
por: Rosenblatt, Joel, et al.
Publicado: (2014)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
por: Kong, Yingying, et al.
Publicado: (2022)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
por: Hoover, Randall, et al.
Publicado: (2017)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China
por: Kong, Yaoyao, et al.
Publicado: (2023)

1164. In vitro Antimicrobial Efficacy of Novel Antimicrobial Dacron Vascular Grafts in the Inhibition of Multidrug-Resistant Gram-Negative Biofilm
por: Vargas-Cruz, Nylev, et al.
Publicado: (2019)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

Updated Review on Clinically-Relevant Properties of Delafloxacin
por: Turban, Adrien, et al.
Publicado: (2023)

In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2017)

In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections
por: McCurdy, S., et al.
Publicado: (2017)

Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin
por: Kocsis, Bela, et al.
Publicado: (2016)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program
por: Flamm, Robert K, et al.
Publicado: (2017)

Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
por: McCurdy, Sandra P., et al.
Publicado: (2022)

2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Foley Catheter with Peri-Urethral Antimicrobial Irrigation for the Prevention of Catheter Associated Urinary Tract Infections – Assessment in an In Vitro Model
por: Rosenblatt, Joel, et al.
Publicado: (2017)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model
por: Craddock, Vaughn D., et al.
Publicado: (2023)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mob3p8pao8qupcma07eecd3pna